Breaking News Instant updates and real-time market news.

MNTA

Momenta

$13.90

-0.25 (-1.77%)

, SHPG

Shire

$174.84

-0.39 (-0.22%)

08:11
11/29/16
11/29
08:11
11/29/16
08:11

Momenta announces M923 clinical study met primary endpoint

Momenta Pharmaceuticals (MNTA) announced that the confirmatory Phase 3 clinical study of M923, a biosimilar HUMIRA candidate developed in collaboration with Baxalta, now part of Shire (SHPG), in patients with moderate-to-severe chronic plaque psoriasis, met its primary endpoint. The proportion of subjects in the study who achieved the primary endpoint, at least 75% reduction in the Psoriasis Area and Severity Index following 16 weeks of treatment, was equivalent between M923 and HUMIRA. The estimated difference in responders was well within the pre-specified confidence interval, confirming equivalence. Equivalence was also achieved in all secondary efficacy endpoints, including the achievement of PASI-50, PASI-90, proportion achieving clear or near-clear skin, and change from baseline in absolute PASI score. Adverse events were comparable in terms of type, frequency, and severity, and were consistent with the published safety data for HUMIRA.

MNTA

Momenta

$13.90

-0.25 (-1.77%)

SHPG

Shire

$174.84

-0.39 (-0.22%)

  • 03

    Dec

MNTA Momenta
$13.90

-0.25 (-1.77%)

09/02/16
LEER
09/02/16
NO CHANGE
LEER
Outperform
Teva third Copaxone patent invalidated as expected, says Leerink
Leerink analyst Jason Gerberry says Teva (TEVA) suffered a largely expected loss in its Copaxone 40mg patent battle, with the Patent Trial and Appeal Board, or PTAB, ruling a third patent invalid. The analyst believes the company will likely appeal the loss, along with PTAB rulings rendered last week that other Copaxone patents were invalid. Gerberry sees the bull case scenario of Teva securing patent exclusivity of the Copaxone 40mg as unlikely and says a settlement with Momenta (MNTA) and Novartis (NVS) is the most logical course of action to mitigate 2017-2018E EPS risk. He reiterates an Outperform rating on Teva's shares.
09/07/16
MAXM
09/07/16
DOWNGRADE
MAXM
Sell
Momenta downgraded to Sell from Hold at Maxim
10/11/16
LEHM
10/11/16
UPGRADE
Target $19
LEHM
Overweight
Momenta upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Douglas Tsao upgraded Momenta Pharmaceuticals to Overweight after attending the consolidated Copaxone 40mg trial. The analyst sees low risk of Momenta being blocked from the 40mg opportunity past 2018 and views the stock's risk/reward as "compelling" at current levels. Tsao believes there is a "good likelihood" that Sandoz, Momenta's partner, launches Copaxone 40mg at-risk as soon as February 2017 upon FDA approval when the 30-month stay expires. The analyst raised his price target for Momenta shares to $19 from $13.
11/22/16
AGIS
11/22/16
INITIATION
Target $15
AGIS
Hold
Momenta initiated with a Hold at Aegis
Aegis analyst Difei Yang iniatied Momenta with a Hold and a $15 price target.
SHPG Shire
$174.84

-0.39 (-0.22%)

11/01/16
BTIG
11/01/16
NO CHANGE
Target $242
BTIG
Buy
Shire's recent weakness overdone, says BTIG
BTIG analyst Timothy Chiang believes the recent selloff in Shire is overdone and that weakness in the Hematology segment was impacted by the timing of large orders. The analyst maintains his Buy rating and $242 price target on Shire shares.
11/02/16
LEER
11/02/16
NO CHANGE
Target $198
LEER
Outperform
Shire price target lowered to $198 from $234 at Leerink
Following a modest Q3 miss, Leerink analyst Jason Gerberry lowered his price target for Shire to $198 from $234 to reflect a more conservative outlook on key franchises due to out-year competitive pressures. The analyst reiterates an Outperform rating on the stock as he believes concerns around pricing look overdone and shares are attractively valued.
11/09/16
SBSH
11/09/16
NO CHANGE
SBSH
Citi sees Healthcare 'relief rally' after Trump win
Citi analyst Andrew Baum expects a "'relief rally" to drive near-term sector outperformance for names in the Healthcare space given the "inability of the Democrats to attain the Presidency, the House or Congress." Longer term, however, the analyst still sees "significant continued legislative risk" for pharma reimbursement. Baum prefers GlaxoSmithKline (GSK), AstraZeneca (AZN), Shire (SHPG) and Roche (RHHBY) among European majors and Bristol-Myers (BMY) and Eli Lilly (LLY) in the U.S.
11/14/16
JPMS
11/14/16
NO CHANGE
JPMS
JPMorgan says Merrimack could fit as target for Shire
JPMorgan analyst Anupam Rama believes Merrimack Pharmaceuticals (MACK) could fit as a potential target for Shire (SHPG). The $1B deal size would be manageable, Rama tells investors in a research note after Ben Harrington's Betaville blog, citing sources, reported Friday that Shire is among the companies participating in Merrimack's strategic review process. Assuming a 40% premium to the intraday Merrimack share price, the deal would be 1% accretive in 2019 and 2% accretive in 2020, Rama estimates.

TODAY'S FREE FLY STORIES

BBRY

BlackBerry

$9.85

0.71 (7.77%)

13:45
09/21/17
09/21
13:45
09/21/17
13:45
Options
BlackBerry call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

13:45
09/21/17
09/21
13:45
09/21/17
13:45
General news
FX Action: USD-JPY »

FX Action: USD-JPY has…

ICPT

Intercept

$98.12

1.92 (2.00%)

13:41
09/21/17
09/21
13:41
09/21/17
13:41
Hot Stocks
Breaking Hot Stocks news story on Intercept »

Intercept selloff…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:40
09/21/17
09/21
13:40
09/21/17
13:40
General news
FX Action: USD-CAD »

FX Action: USD-CAD has…

HDSN

Hudson Technologies

$9.26

-0.03 (-0.32%)

13:39
09/21/17
09/21
13:39
09/21/17
13:39
Technical Analysis
Technical View: Hudson Technologies down on cautious Seeking Alpha mention »

The shares have taken a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Nov

HDSN

Hudson Technologies

$9.26

-0.03 (-0.32%)

13:34
09/21/17
09/21
13:34
09/21/17
13:34
Periodicals
Hudson Technologies mentioned cautiously by Seeking Alpha contributor 

Reference Link

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Nov

OUT

Outfront Media

$21.19

-0.2 (-0.94%)

, LAMR

Lamar Advertising

$64.42

0.45 (0.70%)

13:30
09/21/17
09/21
13:30
09/21/17
13:30
Hot Stocks
Before the Move: Watch Outfront Media ahead of NYC-MTA contract decision »

A decision regarding the…

OUT

Outfront Media

$21.19

-0.2 (-0.94%)

LAMR

Lamar Advertising

$64.42

0.45 (0.70%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

ILG

ILG

$25.87

0.56 (2.21%)

, VAC

Marriott Vacations

$119.30

5.31 (4.66%)

13:24
09/21/17
09/21
13:24
09/21/17
13:24
Periodicals
FrontFour plans ILG proxy fight if deal not struck this year, Bloomberg says »

FrontFour Capital, a…

ILG

ILG

$25.87

0.56 (2.21%)

VAC

Marriott Vacations

$119.30

5.31 (4.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Nov

DDAIF

Daimler AG

$79.46

-0.16 (-0.20%)

, TSLA

Tesla

$373.91

-1.19 (-0.32%)

13:21
09/21/17
09/21
13:21
09/21/17
13:21
Hot Stocks
Mercedes-Benz to start production of electric passenger cars in U.S. »

Mercedes-Benz will set up…

DDAIF

Daimler AG

$79.46

-0.16 (-0.20%)

TSLA

Tesla

$373.91

-1.19 (-0.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

MSFT

Microsoft

$74.94

-0.5 (-0.66%)

13:20
09/21/17
09/21
13:20
09/21/17
13:20
Options
Notable call write in Microsoft »

Notable call write in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 02

    Oct

  • 22

    Oct

$NSD

NASDAQ Market Internals

13:17
09/21/17
09/21
13:17
09/21/17
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

13:16
09/21/17
09/21
13:16
09/21/17
13:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:15
09/21/17
09/21
13:15
09/21/17
13:15
General news
Treasury's $11 B 10-year TIPS reopening was poorly received »

Treasury's $11 B…

XOP

SPDR Oil Exploration and Production Fund

$32.88

0.02 (0.06%)

13:10
09/21/17
09/21
13:10
09/21/17
13:10
Options
Hefty put spread in SPDR Oil and Gas Exploration ETF »

Hefty put spread in SPDR…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRIP

TripAdvisor

$43.92

0.32 (0.73%)

13:05
09/21/17
09/21
13:05
09/21/17
13:05
Options
TripAdvisor call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:04
09/21/17
09/21
13:04
09/21/17
13:04
General news
10-Yr TIPS Auction Coupon Rate data reported »

10-Yr TIPS Auction Coupon…

13:04
09/21/17
09/21
13:04
09/21/17
13:04
General news
10-Yr TIPS Auction Total Amount data reported »

10-Yr TIPS Auction Total…

ZGNX

Zogenix

$13.60

-0.95 (-6.53%)

12:55
09/21/17
09/21
12:55
09/21/17
12:55
Options
Zogenix put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IPXL

Impax

$21.55

0.6 (2.86%)

12:51
09/21/17
09/21
12:51
09/21/17
12:51
Periodicals
Impax merger with Amneal could come next month, WSJ reports »

Impax and Amneal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

CAR

Avis Budget

$37.92

1.28 (3.49%)

12:40
09/21/17
09/21
12:40
09/21/17
12:40
Options
Avis attracts a put buyer »

Avis attracts a put…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Nov

12:40
09/21/17
09/21
12:40
09/21/17
12:40
General news
Treasury 10-year TIPS preview »

Treasury 10-year TIPS…

GIS

General Mills

$51.80

-0.3658 (-0.70%)

12:30
09/21/17
09/21
12:30
09/21/17
12:30
Options
Position adjustment in General Mills after earnings »

Position adjustment in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ERIC

Ericsson

$5.60

-0.08 (-1.41%)

12:29
09/21/17
09/21
12:29
09/21/17
12:29
Upgrade
Ericsson rating change  »

Ericsson upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NOK

Nokia

$6.09

-0.095 (-1.54%)

12:29
09/21/17
09/21
12:29
09/21/17
12:29
Downgrade
Nokia rating change  »

Nokia downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOGL

Alphabet Class A

$947.54

10.68 (1.14%)

, TWTR

Twitter

$17.59

-0.035 (-0.20%)

12:26
09/21/17
09/21
12:26
09/21/17
12:26
Periodicals
Google, Twitter could be involved in investigation on Russia, Recode reports »

The congressional…

GOOGL

Alphabet Class A

$947.54

10.68 (1.14%)

TWTR

Twitter

$17.59

-0.035 (-0.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.